Pain Management News

The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer.

Treatment with IV edaravone for ALS was linked to a slowing of disease-progression milestones compared with no IV edaravone treatment, results of an administrative claims analysis show.

The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a press release.

The FDA has granted 510(k) clearance to a Bay Area commercial stage medical technology company for its novel large-bore catheter stroke thrombectomy system.

Among post-9/11 United States military veterans, mild traumatic brain injury was associated with unfavorable long-term outcomes, such as severe PTSD, when occurring around a traumatic event, researchers wrote in JAMA Network Open.

In a large cohort of patients with autoimmune diseases, treatment with biologic disease-modifying antirheumatic drugs was associated with reduced incidence of Parkinson’s disease, data show.

LOS ANGELES — Treatment with cannabidiol led to improved seizure and nonseizure outcomes in patients with various forms of epilepsy, data show.

Treatment with tofersen in patients with superoxide 1 dismutase 1 ALS was linked to preservation of motor function, maintenance of muscle strength and reduction of disease-specific biomarkers, data show.

The average wait time between a referral and neurologist visit was more than a month among older adults, with longer wait times for those with serious neurodegenerative conditions like MS, epilepsy and Parkinson’s disease, new research shows.